Read More Pharma Industry News Why AnaptysBio’s new CFO hire may matter more than a routine biotech appointment AnaptysBio is no longer a classic biotech pipeline bet. Christopher Murphy’s CFO appointment tests whether ANAB can execute as a royalty vehicle. byPallavi MadhirajuMay 11, 2026